Corrigendum to "Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18": [ESMO Open 8 (2023) 101588]

Affiliations

• ¹ Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul; Cancer Research Institute, Seoul National University College of Medicine, Seoul.
• ² Department of Oncology and Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul.
• ³ Division of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul.
• ⁴ Department of Hemato-Oncology, Chonnam National University Medical School & Hwasun Hospital, Hwasun.
• ⁵ Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon.
• ⁶ Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon.
• ⁷ Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul.
• ⁸ Lunit, Seoul, Republic of Korea.
• ⁹ Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul; Cancer Research Institute, Seoul National University College of Medicine, Seoul. Electronic address: [email protected].